Loading
In a small trial, the antibody-drug conjugate trastuzumab deruxtecan shrank brain metastases in almost three quarters of women with HER2-positive breast cancer, showing that a large antibody-based drug can work inside the brain.
Single-arm phase 2 trial of 15 patients with HER2-positive breast cancer and newly diagnosed or progressing brain metastases not needing immediate local therapy, treated with trastuzumab deruxtecan 5.4 mg/kg.
Intracranial response by RANO-BM criteria was 73.3 percent in the intention-to-treat population, with a median progression-free survival of 14 months and preserved quality of life. The larger DESTINY-Breast12 study later confirmed intracranial activity in a broader population.
Trastuzumab deruxtecan is an option for active HER2-positive brain metastases, complementing tucatinib-based therapy, and challenges the assumption that antibody-drug conjugates cannot reach the brain.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab deruxtecan.
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
Shares Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-positive breast cancer with brain metastases, Trastuzumab.
Shares Trastuzumab deruxtecan, Trastuzumab.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab deruxtecan.